Enhanced Blood Pressure Response to Mineralocorticoid Stimulation in Normotensive Members of Hypertensive Families

Abstract
Currently normotensive offspring of essential hypertensive parents often have disturbances in blood pressure (BP) regulation such as abnormalities in electrolyte homoeostasis, increased salt-sensitivity and/or impaired renal Na+-excretion. Whether an altered reactivity to mineralocorticoids may also play a role is presently unknown. Therefore, we investigated BP (recorded during 24 h), plasma atrial natriuretic factor (ANF), cyclic guanosine monophosphate (cGMP), aldosterone (PA) and renin activity (PRA), 24-h urine electrolyte and cGMP excretions measured on 4 consecutive days, as well as other variables, after I week on placebo and after 3 weeks of 9α-fludrocortisoneacetate (9αF) administration, 0.6 mg/d in 12 normotensive sons of essential hypertensive parents (SEH) and 12 body-mass-index- and age-matched (25 ±1[± SEM]yr) sons of normotensive parents (SN). On placebo, the 2 groups did not differ significantly in average 24 h BP (mean BP 95 ± 2 vs 95 ± 2 mmHg), plasma-ANF (40 ± 7 vs 30 ± 5 pg/ml), cGMP (6 ± 0.4 vs 6 ±0.5 nmol/1), PRA (1.3 ± 0.1 vs 1.6 ± 0.2 ng/ml/h), PA (9 ± 0.5 vs 10 ± 0.9 ng/dl), hematocrit (44 ±0.7 vs 44 ± 0.4%) and 96-h urinary-Na+ (mean 205 ± 19 vs 195 ± 16mmol/d), -K+ (69 ± 6 vs 78 ± 7 mmol/d) or -cGMP (461 ± 35 vs 483 ± 32 nmol/d). 9αF significantly increased BP in SEH (p < 0.005) but not SN (107 ± 2 vs 100 ± 2 mmHg, pp+ (205 ± 19 vs 195 ± 17 mmol/d)-K+ (80 ± 8 vs 69 ± 6 mmol/d) or -cGMP (673 ± 76 vs 653 ± 62 nmol/d), plasma-Na± (increase + 3 vs + 2 mmol/1), K+ (decrease –0.5 vs –0.5 mmol/1), hematocrit (42 ± 0.8 vs 42 ±0.2%) or body weight (increase + 2.0 vs + 1.9 kg). These results indicate that normotensive offspring of hypertensive parents may react to mineralocorticoid stimulation with an enhanced BP-increase. This disturbance cannot be explained by insufficient renin-aldosterone suppression, inadequate ANF stimulation or abnormally increased N+ -fluid retention.